(Q36448693)

14 August 2017

1 reference

title

Management of prostate cancer. Part 2: localized and locally advanced disease (English)

1 reference

14 August 2017

author

Prasanna Sooriakumaran

series ordinal

1

object named as

Prasanna Sooriakumaran

1 reference

14 August 2017

Sara Jane Khaksar

2

1 reference

14 August 2017

Jyoti Shah

series ordinal

3

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Expert Review of Anticancer Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

595-603

1 reference

14 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Biological determinants of cancer progression in men with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Active surveillance: towards a new paradigm in the management of early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Prostate brachytherapy has come of age: a review of the technique and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

High-Intensity Focused Ultrasound and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Delta-aminolevulinic acid-mediated photosensitization of prostate cell lines: implication for photodynamic therapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Interstitial microwave thermal therapy for prostate cancer: method of treatment and results of a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Emerging minimally invasive techniques for treating localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

A systematic overview of radiation therapy effects in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

The impact of prostate size in laparoscopic radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Surgical management of prostate cancer: advances based on a rational approach to the data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Management of high-risk populations with locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

The role of high-dose rate brachytherapy in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Early prostate cancer: clinical decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Quality-of-life outcomes in men treated for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Some notes about the usage of the Charlson co-morbidity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Understanding and appreciating overdiagnosis in the PSA era

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Cryosurgery for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Hormonal treatment before radical prostatectomy: a 3-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

A pilot study of intermittent androgen deprivation in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

Intermittent androgen suppression in the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.4.595

21 January 2018

Identifiers

DOI

10.1586/14737140.6.4.595

1 reference

14 August 2017

1 reference